Laser and Post-Herpetic Neuralgia

High intensity Laser therapy versus Placebo control for truncal Post-Herpetic Neuralgia: A Randomized double-blind trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202411705957181

Enrollment

Registered

2024-11-05

Start date

2024-07-10

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases Skin and Connective Tissue Diseases

Interventions

High intensity laser therapy HILT and transcutaneous electrical nerve stimulation TENS and Hot packs

Placebo HILT and Transcutaneous Electrical Nerve Stimulation TENS and hot packs for pain relief

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: males and females age of 45 up to70 diagnosed as PHN after Herps Zoster infection (Shingles) suffering from PHN from 6 to 1 year do not receive LASER therapy for any cause before

Exclusion criteria

Exclusion criteria: patient with diabetes patients those exposed to chemical irritators any metabolic conditions swelling and/or edema trauma in affected area surgery in affected area chronic renal insufficiency

Design outcomes

Primary

Measure	Time frame
chronic neuropathic pain	—

Secondary

Measure	Time frame
insomnia	—

Countries

Egypt

Contacts

Public ContactRawya Alshahawy

lecturer

drgigi2008@yahoo.com00201142366446

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026